Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 3
1980 1
1982 2
1983 1
1984 1
1986 2
1987 1
1990 3
1992 2
1993 3
1994 6
1995 5
1996 7
1997 5
1998 5
1999 4
2000 2
2001 5
2002 8
2003 5
2004 10
2005 2
2006 6
2007 10
2008 12
2009 12
2010 17
2011 17
2012 13
2013 17
2014 20
2015 24
2016 24
2017 29
2018 37
2019 35
2020 36
2021 26
2022 40
2023 27
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Results by year

Filters applied: . Clear all
Page 1
Giant Cell Tumor of Bone: An Update.
Basu Mallick A, Chawla SP. Basu Mallick A, et al. Curr Oncol Rep. 2021 Mar 22;23(5):51. doi: 10.1007/s11912-021-01047-5. Curr Oncol Rep. 2021. PMID: 33754215 Review.
PURPOSE OF REVIEW: To highlight the new developments in the management of advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was traditionally managed with surgery alone by either curettage and local adjuvant therap …
PURPOSE OF REVIEW: To highlight the new developments in the management of advanced giant cell tumor of bone …
Giant cell tumour of bone.
Aoude A, Nikomarov D, Perera JR, Ibe IK, Griffin AM, Tsoi KM, Ferguson PC, Wunder JS. Aoude A, et al. Bone Joint J. 2023 May 1;105-B(5):559-567. doi: 10.1302/0301-620X.105B5.BJJ-2022-1231.R1. Bone Joint J. 2023. PMID: 37121582
Narlumosbart: First Approval.
Dhillon S. Dhillon S. Drugs. 2024 Jan;84(1):105-109. doi: 10.1007/s40265-023-01985-3. Drugs. 2024. PMID: 38112898 Review.
In September 2023, narlumosbart received conditional first approval in China for the treatment of adults with GCTB that is unresectable or when surgical resection would result in severe functional disability. Clinical studies of narlumosbart for bone metastases, postmenopa …
In September 2023, narlumosbart received conditional first approval in China for the treatment of adults with GCTB that is unresectable or w …
Current management of giant-cell tumor of bone in the denosumab era.
Nagano A, Urakawa H, Tanaka K, Ozaki T. Nagano A, et al. Jpn J Clin Oncol. 2022 May 5;52(5):411-416. doi: 10.1093/jjco/hyac018. Jpn J Clin Oncol. 2022. PMID: 35199172 Review.
Giant-cell tumor of bone is a rare, locally aggressive and rarely metastasizing primary bone tumor. ...In systematic reviews of the local recurrence rate after preoperative use of denosumab, conclusions vary due to the small sample sizes of the …
Giant-cell tumor of bone is a rare, locally aggressive and rarely metastasizing primary bone tumor. ...In …
Locally Aggressive Connective Tissue Tumors.
Gounder MM, Thomas DM, Tap WD. Gounder MM, et al. J Clin Oncol. 2018 Jan 10;36(2):202-209. doi: 10.1200/JCO.2017.75.8482. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220303 Free PMC article. Review.
In this review, we highlight the complexities of the natural history, biology, and clinical management of three intermediate connective tissue tumors: desmoid tumor (DT) or aggressive fibromatosis, tenosynovial giant cell tumor (TGCT) or diffuse-type pigmented villonodular …
In this review, we highlight the complexities of the natural history, biology, and clinical management of three intermediate connecti …
Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis.
Tan X, Zhang Y, Wei D, Yang Y, Xiang F. Tan X, et al. Clin Exp Med. 2023 Nov;23(7):3053-3075. doi: 10.1007/s10238-023-01079-0. Epub 2023 Apr 27. Clin Exp Med. 2023. PMID: 37103655 Review.
Denosumab, as a neoadjuvant therapy, provides new possibilities for treating GCTB. However, even after multiple studies and long-term clinical trials, there are limitations in the treatment process. Research data and Medical Subject Headings terms related to denosumab and …
Denosumab, as a neoadjuvant therapy, provides new possibilities for treating GCTB. However, even after multiple studies and long-term cli …
Giant cell tumor of bone.
Yasko AW. Yasko AW. Curr Oncol Rep. 2002 Nov;4(6):520-6. doi: 10.1007/s11912-002-0067-2. Curr Oncol Rep. 2002. PMID: 12354366 Review.
Giant cell tumor of bone is an enigmatic osseous neoplasm that is histologically benign but clinically shows local aggression and metastatic potential. ...In this report, the clinicopathologic features of and current treatment approaches to g …
Giant cell tumor of bone is an enigmatic osseous neoplasm that is histologically benign but clinically sh …
The multidisciplinary management of giant cell tumor of bone.
Ng VY, Davidson DJ, Kim EY, Pollack SM, Conrad Iii EU, Jones RL. Ng VY, et al. Expert Rev Anticancer Ther. 2014 Jul;14(7):783-90. doi: 10.1586/14737140.2014.901891. Epub 2014 Mar 26. Expert Rev Anticancer Ther. 2014. PMID: 24666240 Review.
Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in a small proportion of patients, metastatic disease can develop. ...
Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in …
Giant cell tumour of bone in the denosumab era.
van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H. van der Heijden L, et al. Eur J Cancer. 2017 May;77:75-83. doi: 10.1016/j.ejca.2017.02.021. Epub 2017 Mar 30. Eur J Cancer. 2017. PMID: 28365529 Review.
Updated concepts in treatment of giant cell tumor of bone.
van der Heijden L, Lipplaa A, van Langevelde K, Bovée JVMG, van de Sande MAJ, Gelderblom H. van der Heijden L, et al. Curr Opin Oncol. 2022 Jul 1;34(4):371-378. doi: 10.1097/CCO.0000000000000852. Curr Opin Oncol. 2022. PMID: 35837707 Review.
PD-L1 expression can be used as biological marker to predict higher recurrence risks in GCTB patients.The use of bisphosphonate-loaded bone cement is under investigation in a randomized controlled trial. A new technique consisting of percutaneous microwave ablation …
PD-L1 expression can be used as biological marker to predict higher recurrence risks in GCTB patients.The use of bisphosphonate-loaded bone …
443 results